| CYTOSORBENTS CORP. DL-,01 |
| USA |
| Gesundheit |
| US23283X2062 / A12GDU |
| HQE1 (Frankfurt) / CTSO (NASDAQ) |
| FRA:HQE1, ETR:HQE1, HQE1:GR, NASDAQ:CTSO |
| - |
| http://www.cytosorbents.c.. |
|
Cytosorbents Corporation is a biotechnology company that specializes in advanced blood purification technologies designed to treat life-threatening conditions in intensive care units and other hospital settings. The company's flagship product, CytoSo..
>Volltext.. |
| 29.73 Mio. EUR |
| 49.18 Mio. EUR |
| 32.11 Mio. EUR |
| -10.92 Mio. EUR |
| -7.1 Mio. EUR |
| -0.11 EUR |
| 25.22 Mio. EUR |
| 5.41 Mio. EUR |
| - |
| - |
| -8.22% |
| 65.12% |
| - |
| - |
| - |
| - |
| CYTOSORBENTS |
| 05.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|